Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 102.85m |
Free float | 53.35m |
P/E (TTM) | -- |
Market cap | 11.10m USD |
EPS (TTM) | -0.1708 USD |
--
More ▼
Announcements
- Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
- Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
- Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
- Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
- Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
- Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
- Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
- Conduit Pharmaceuticals to Join Russell 3000® Index
- Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
More ▼